ArticleScience translational medicine2017

Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation.

Elizabeth Allen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.